Workflow
涨停次日紧急易主,接盘方成立不足一个月

Core Viewpoint - The article discusses the recent transfer of control at Yonghe Fluid Intelligent Control Co., Ltd. (Yonghe Zhikong), highlighting the sale of shares by its controlling shareholder, which has led to significant stock price fluctuations and reflects ongoing challenges in the company's strategic direction and performance [1][4][10]. Group 1: Share Transfer Details - Yonghe Zhikong's controlling shareholder, Cao Deli, signed a share transfer agreement with Hangzhou Runfeng, transferring 35.66 million shares (8% of total shares) at a price of 8.9736 yuan per share, totaling approximately 320 million yuan [1][4]. - Following the transfer, Hangzhou Runfeng will hold 8% of Yonghe Zhikong's shares and 14.65% of voting rights, making it the new controlling shareholder [1][4]. - The share transfer price represents a premium of over 45% compared to Yonghe Zhikong's closing price on August 6 [4]. Group 2: Historical Context and Previous Attempts - This is not the first time Yonghe Zhikong has sought a new controlling shareholder; previous attempts included a planned transfer to Guangdong Pule Green Energy Holdings, which ultimately fell through [4][5][6]. - Cao Deli's persistent efforts to divest control indicate a strategic shift, as he has been involved in multiple capital operations since taking control in November 2019 [4][6]. Group 3: Business Performance and Challenges - Yonghe Zhikong's main business segments include plumbing valves (85% of revenue), precision radiation therapy (14.39%), and photovoltaic (0.24%) [8]. - The company's foray into the medical field has not yielded significant results, with medical revenue dropping by 19.77% in 2024 compared to 2023, and a low gross margin of 7.96% [9]. - The photovoltaic segment has also underperformed, generating less than 20 million yuan in revenue in 2024, with a gross margin of -3020.96% [9][10]. Group 4: Future Outlook - Cao Deli has committed to facilitating the divestment of Yonghe Zhikong's underperforming photovoltaic and medical assets by December 20, 2025, as part of the control transfer agreement [10].